Nanostructured bacterial materials for innovative medicines

Trends in Microbiology

Volumn 18, Issue 9, 2010, Pages 423-430

  Rodríguez Carmona, Escarlata ^a,b   Villaverde, Antonio ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; ANTISENSE OLIGODEOXYNUCLEOTIDE; BACTERIOPHAGE DNA; BIOMATERIAL; CADMIUM; CADMIUM SULFIDE; CLARITHROMYCIN; CYANOPHYCIN; DEXTRAN; DOXORUBICIN; GATIFLOXACIN; GELLAN; GOLD; GOLD NANOPARTICLE; HYALURONIC ACID; HYGROMYCIN; IRON; MAGNETITE; NANOCRYSTAL; NANOMATERIAL; POLYGLUTAMIC ACID; POLYHYDROXYALKANOIC ACID; POLYLYSINE; PREDNISOLONE; SILVER; SILVER NANOPARTICLE; UNINDEXED DRUG; XANTHAN; ZINC; ZINC SULFIDE;

AEROMONAS; AZOTOBACTER VINELANDII; BACILLUS; BACILLUS LICHENIFORMIS; BACILLUS SUBTILIS; BACTERIAL CELL; BACTERIOLOGY; BACTERIOPHAGE; BIOCOMPATIBILITY; BIOMEDICINE; BIOSENSOR; CYANOBACTERIUM; DRUG DELIVERY SYSTEM; ESCHERICHIA COLI; HYDROGEL; LACTOBACILLUS BREVIS; LEUCONOSTOC MESENTEROIDES; MAGNETOSPIRILLUM; METABOLIC ENGINEERING; METHODOLOGY; NANOIMAGING; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; RALSTONIA; REVIEW; RHODOBACTER; RHODOBACTER CAPSULATUS; RHODOPSEUDOMONAS PALUSTRIS; SPHINGOMONAS PAUCIMOBILIS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS EQUI; STREPTOCOCCUS MUTANS; STREPTOMYCES; SYNTHESIS; SYSTEMS BIOLOGY; TISSUE ENGINEERING; VIRUS LIKE AGENT; WOUND DRESSING; XANTHOMONAS CAMPESTRIS;

BACTERIA; BACTERIOPHAGES; BIOCOMPATIBLE MATERIALS; BIOMEDICAL ENGINEERING; BIOPOLYMERS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; METAL NANOPARTICLES; NANOPARTICLES; NANOSTRUCTURES; NANOTECHNOLOGY; PHARMACEUTICAL PREPARATIONS; SURFACE PROPERTIES; TISSUE ENGINEERING;

BACTERIA (MICROORGANISMS);

EID: 77956187956     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tim.2010.06.007     Document Type: Review

References (84)

1. Lee S.Y., et al. Metabolic engineering of microorganisms: general strategies and drug production. Drug Discov. Today 2009, 14:78-88.
2. Riehemann K., et al. Nanomedicine - challenge and perspectives. Angew. Chem. Int. Ed. Engl. 2009, 48:872-897.
3. Bajaj I.B., et al. Gellan gum: fermentative production, downstream processing and applications. Food Technol. Biotechnol. 2007, 45:341-354.
4. Kumar A.S., Mody K. Microbial exopolysaccharides: variety and potential applications. Microbial Production of Biopolymers and Polymer Precursors: Applications and Perspectives 2009, 229-253. Caister Academic Press. B. Rehm (Ed.).
5. Naessens M., et al. Dextran dextrinase and dextran of Gluconobacter oxydans. J. Ind. Microbiol. Biotechnol. 2005, 32:323-334.
6. Brondsted H., et al. Crosslinked dextran - a new capsule material for colon targeting of drugs. J. Control Release 1998, 53:7-13.
7. Pereswetoff-Morath L. Microspheres as nasal drug delivery systems. Adv. Drug Deliv. Rev. 1998, 29:185-194.
8. Maire M., et al. Bovine BMP osteoinductive potential enhanced by functionalized dextran-derived hydrogels. Biomaterials 2005, 26:5085-5092.
9. Becker A., Vorhoelter F.J. Xanthan biosynthesis by Xanthomonas bacteria: an overview of the current biochemical and genomic data. Microbial Production of Biopolymers and Polymer Precursors: Applications and Perspectives 2009, 1-11. Caister Academic Press. B. Rehm (Ed.).
10. Bertram U., Bodmeier R. In situ gelling, bioadhesive nasal inserts for extended drug delivery: In vitro characterization of a new nasal dosage form. Eur. J. Pharm. Sci. 2006, 27:62-71.
11. Rajinikanth P.S., Mishra B. Stomach-site specific drug delivery system of clarithromycin for eradication of Helicobacter pylori. Chem. Pharm. Bull. (Tokyo) 2009, 57:1068-1075.
12. Sabra W., Zeng A.P. Microbial production of alginates: physiology and process aspects. Alginates: Biology and Applications 2009, 153-173. Springer. B. Rehm (Ed.).
13. Remminghorst U., Rehm B.H. Bacterial alginates: from biosynthesis to applications. Biotechnol. Lett. 2006, 28:1701-1712.
14. Mirshafiey A., Rehm B.H. Alginate and its comonomer mannuronic acid: medical relevance as drugs. Microbial Production of Biopolymers and Polymer Precursors: Applications and Perspectives 2009, 229-260. Caister Academic Press. B. Rehm (Ed.).
15. Larsen N.E., Balazs E.A. Drug delivery systems using hyaluronan and its derivatives. Adv. Drug Deliv. Rev. 1991, 7:279-293.
16. Peattie R.A., et al. Stimulation of in vivo angiogenesis by cytokine-loaded hyaluronic acid hydrogel implants. Biomaterials 2004, 25:2789-2798.
17. Shih I.L., et al. Microbial synthesis of poly(epsilon-lysine) and its various applications. Bioresour. Technol. 2006, 97:1148-1159.
18. Candela T., et al. Fusobacterium nucleatum, the first Gram-negative bacterium demonstrated to produce polyglutamate. Can. J. Microbiol. 2009, 55:627-632.
19. Buescher J.M., Margaritis A. Microbial biosynthesis of polyglutamic acid biopolymer and applications in the biopharmaceutical, biomedical and food industries. Crit. Rev. Biotechnol. 2007, 27:1-19.
20. Hezayen F.F., et al. Transfer of Natrialba asiatica B1T to Natrialba taiwanensis sp. nov. and description of Natrialba aegyptiaca sp. nov., a novel extremely halophilic, aerobic, non-pigmented member of the Archaea from Egypt that produces extracellular poly(glutamic acid). Int. J. Syst. Evol. Microbiol. 2001, 51:1133-1142.
21. Murakami S., Aoki N. Bio-based hydrogels prepared by cross-linking of microbial poly(gamma-glutamic acid) with various saccharides. Biomacromolecules 2006, 7:2122-2127.
22. Matsusaki M., Akashi M. Novel functional biodegradable polymer IV: pH-sensitive controlled release of fibroblast growth factor-2 from a poly(gamma-glutamic acid)-sulfonate matrix for tissue engineering. Biomacromolecules 2005, 6:3351-3356.
23. Liang H.F., et al. Preparation of nanoparticles composed of poly(gamma-glutamic acid)-poly(lactide) block copolymers and evaluation of their uptake by HepG2 cells. J. Control Release 2005, 105:213-225.
24. Saimura M., et al. Biosynthesis of nearly monodispersed poly(epsilon-L-lysine) in Streptomyces species. Biotechnol. Lett. 2008, 30:377-385.
25. Lockau W., Ziegler K. Cyanophycin inclusions: biosynthesis and applications. Microbial Bionanotechnology: Biological Self-assembly Systems and Biopolymer-based Nanostructures 2006, 79-106. Taylor & Francis. B. Rehm (Ed.).
26. Sallam A., et al. Biotechnological process for production of beta-dipeptides from cyanophycin on a technical scale and its optimization. Appl. Environ. Microbiol. 2009, 75:29-38.
27. Nakanishi T., et al. Development of the polymer micelle carrier system for doxorubicin. J. Control Release 2001, 74:295-302.
28. Chen C.Q. A microbial polyhydroxyalkanoates (PHA) based bio- and materials industry. Chem. Soc. Rev. 2009, 38:2434-2446.
29. Rehm B.H., Steinbuchel A. Biochemical and genetic analysis of PHA synthases and other proteins required for PHA synthesis. Int. J. Biol. Macromol. 1999, 25:3-19.
30. Lee S.Y. Bacterial polyhydroxyalkanoates. Biotechnol. Bioeng. 1996, 49:1-14.
31. Qiong W., et al. Medical application of microbial biopolyesters polyhydroxyalkanoates. Artif. Cells Blood Substit. Immobil. Biotechnol. 2009, 37:1-12.
32. Remminghorst U., Rehm B.H. Microbial production of alginate: biosynthesis and applications. Microbial Production of Biopolymers and Polymer Precursors: Applications and Perspectives 2009, 13-42. Caister Academic Press. B. Rehm (Ed.).
33. Mellors R., et al. Preparation of self-assembled microspheres and their potential for drug delivery. Pharm. Dev. Technol. 2010, 15:105-111.
34. Ibrahim H.K., et al. Mucoadhesive nanoparticles as carrier systems for prolonged ocular delivery of gatifloxacin/prednisolone bitherapy. Mol. Pharm. 2010, 7:576-585.
35. Ossipov, D.A. (2010) Nanostructured hyaluronic acid-based materials for active delivery to cancer. Expert Opin. Drug Deliv. 7, 681-703.
36. Choi K.Y., et al. Self-assembled hyaluronic acid nanoparticles for active tumor targeting. Biomaterials 2010, 31:106-114.
37. Portilla-Arias J.A., et al. Nanoparticles made of microbial poly(gamma-glutamate)s for encapsulation and delivery of drugs and proteins. J. Biomater. Sci. Polym. Ed. 2009, 20:1065-1079.
38. Akagi T., et al. Stabilization of polyion complex nanoparticles composed of poly(amino acid) using hydrophobic interactions. Langmuir 2010, 26:2406-2413.
39. Grage K., et al. Bacterial polyhydroxyalkanoate granules: biogenesis, structure, and potential use as nano-/micro-beads in biotechnological and biomedical applications. Biomacromolecules 2009, 10:660-669.
40. Grage K., et al. Polyhydroxyalkanoates: from bacterial storage compound via renewable plastic to bio-bead. Microbial Production of Biopolymers and Polymer Precursors: Applications and Perspectives 2009, 255-287. Caister Academic Press. B. Rehm (Ed.).
41. Atwood J.A., Rehm B.H. Protein engineering towards biotechnological production of bifunctional polyester beads. Biotechnol. Lett. 2009, 31:131-137.
42. Yao Y.C., et al. A specific drug targeting system based on polyhydroxyalkanoate granule binding protein PhaP fused with targeted cell ligands. Biomaterials 2008, 29:4823-4830.
43. Bai H.J., et al. Biosynthesis of cadmium sulfide nanoparticles by photosynthetic bacteria Rhodopseudomonas palustris. Colloids Surf. B Biointerfaces 2009, 70:142-146.
44. Sweeney R.Y., et al. Bacterial biosynthesis of cadmium sulfide nanocrystals. Chem. Biol. 2004, 11:1553-1559.
45. Chen Y.L., et al. Augmented biosynthesis of cadmium sulfide nanoparticles by genetically engineered Escherichia coli. Biotechnol. Prog. 2009, 25:1260-1266.
46. Wangoo N., et al. Facile synthesis and functionalization of water-soluble gold nanoparticles for a bioprobe. Anal. Chim. Acta 2008, 610:142-148.
47. He S., et al. Biological synthesis of gold nanowires using extract of Rhodopseudomonas capsulata. Biotechnol Prog. 2008, 24:476-480.
48. Vaidyanathan R., et al. Enhanced silver nanoparticle synthesis by optimization of nitrate reductase activity. Colloids Surf. B Biointerfaces 2010, 75:335-341.
49. Gurunathan S., et al. Biosynthesis, purification and characterization of silver nanoparticles using Escherichia coli. Colloids Surf. B Biointerfaces 2009, 74:328-335.
50. Marin S., Merkoçi A. Direct electrochemical stripping detection of cystic-fibrosis-related DNA linked through cadmium sulfide quantum dots. Nanotechnology 2009, 20:55101.
51. Alvarez H., et al. Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy. Nanomedicine 2008, 4:295-301.
52. Kalishwaralal K., et al. Silver nanoparticles inhibit VEGF induced cell proliferation and migration in bovine retinal endothelial cells. Colloids Surf. B Biointerfaces 2009, 73:51-57.
53. Cheng F.Y., et al. Comparative efficiencies of photothermal destruction of malignant cells using antibody-coated silica@Au nanoshells, hollow Au/Ag nanospheres and Au nanorods. Nanotechnology 2009, 20:425104.
54. Arakaki A., et al. Formation of magnetite by bacteria and its application. J. R. Soc. Interface 2008, 5:977-999.
55. Tanaka T., et al. Novel method for selection of antimicrobial peptides from a phage display library by use of bacterial magnetic particles. Appl. Environ. Microbiol. 2008, 74:7600-7606.
56. Sun J.B., et al. Preparation and anti-tumor efficiency evaluation of doxorubicin-loaded bacterial magnetosomes: magnetic nanoparticles as drug carriers isolated from Magnetospirillum gryphiswaldense. Biotechnol. Bioeng. 2008, 101:1313-1320.
57. Xiang L., et al. Bacterial magnetic particles (BMPs)-PEI as a novel and efficient non-viral gene delivery system. J. Gene Med. 2007, 9:679-690.
58. Corchero J.L., Villaverde A. Biomedical applications of distally controlled magnetic nanoparticles. Trends Biotechnol. 2009, 27:468-476.
59. Ohuchi S., Schuler D. In vivo display of a multisubunit enzyme complex on biogenic magnetic nanoparticles. Appl. Environ. Microbiol. 2009, 75:7734-7738.
60. Ding Y., et al. Deletion of the ftsZ-like gene results in the production of superparamagnetic magnetite magnetosomes in Magnetospirillum gryphiswaldense. J. Bacteriol. 2010, 192:1097-1105.
61. Sun J.B., et al. High-yield growth and magnetosome formation by Magnetospirillum gryphiswaldense MSR-1 in an oxygen-controlled fermentor supplied solely with air. Appl. Microbiol. Biotechnol. 2008, 79:389-397.
62. Thurber R.V. Current insights into phage biodiversity and biogeography. Curr. Opin. Microbiol. 2009, 12:582-587.
63. O'Flaherty S., et al. Bacteriophage and their lysins for elimination of infectious bacteria. FEMS Microbiol. Rev. 2009, 33:801-819.
64. Khalil A.S., et al. Single M13 bacteriophage tethering and stretching. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:4892-4897.
65. Nam K.T., et al. Virus-enabled synthesis and assembly of nanowires for lithium ion battery electrodes. Science 2006, 312:885-888.
66. Petty N.K., et al. Biotechnological exploitation of bacteriophage research. Trends Biotechnol. 2007, 25:7-15.
67. Mao C., et al. Viral assembly of oriented quantum dot nanowires. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:6946-6951.
68. Bar H., et al. Killing cancer cells by targeted drug-carrying phage nanomedicines. BMC Biotechnol. 2008, 8:37.
69. Li L., et al. Evaluation of specific delivery of chimeric phi29 pRNA/siRNA nanoparticles to multiple tumor cells. Mol. Biosyst. 2009, 5:1361-1368.
70. Wendell D., et al. Translocation of double-stranded DNA through membrane-adapted phi29 motor protein nanopores. Nat. Nanotechnol. 2009, 4:765-772.
71. Wu M., et al. Delivery of antisense oligonucleotides to leukemia cells by RNA bacteriophage capsids. Nanomedicine 2005, 1:67-76.
72. Bundy B.C., et al. Escherichia coli-based cell-free synthesis of virus-like particles. Biotechnol. Bioeng. 2008, 100:28-37.
73. Lee C.D., et al. Production of FMDV virus-like particles by a SUMO fusion protein approach in Escherichia coli. J. Biomed. Sci. 2009, 16:69.
74. Steinmetz N.F., et al. Buckyballs meet viral nanoparticles: candidates for biomedicine. J. Am. Chem. Soc. 2009, 131:17093-17095.
75. Vazquez E., et al. Protein nanodisk assembling and intracellular trafficking powered by an arginine-rich (R9) peptide. Nanomedicine 2010, 5:259-268.
76. Ferrer-Miralles N., et al. Microbial factories for recombinant pharmaceuticals. Microb. Cell Fact. 2009, 8:17.
77. Gasser B., et al. Protein folding and conformational stress in microbial cells producing recombinant proteins: a host comparative overview. Microb. Cell Fact. 2008, 7:11.
78. Martinez-Alonso M., et al. Learning about protein solubility from bacterial inclusion bodies. Microb. Cell Fact. 2009, 8:4.
79. Garcia-Fruitos E., et al. Surface cell growth engineering assisted by a novel bacterial nanomaterial. Adv. Mater. 2009, 21:4249-4253.
80. Garcia-Fruitos E., et al. Tunable geometry of bacterial inclusion bodies as substrate materials for tissue engineering. Nanotechnology 2010, 21:205101.
81. Diez-Gil C., et al. The nanoscale properties of bacterial inclusion bodies and their effect on mammalian cell proliferation. Biomaterials 2010, 31:5805-5812.
82. Miyazaki S., et al. Comparison of in situ gelling formulations for the oral delivery of cimetidine. Int. J. Pharm. 2001, 220:161-168.
83. Shimizu K., et al. Construction of multi-layered cardiomyocyte sheets using magnetite nanoparticles and magnetic force. Biotechnol. Bioeng. 2007, 96:803-809.
84. Mao C., et al. Virus-based toolkit for the directed synthesis of magnetic and semiconducting nanowires. Science 2004, 303:213-217.